Claims for Patent: 7,416,858

Summary for Patent: 7,416,858

Title:	Pharmaceutical compositions of glycoconjugates
Abstract:	The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group of peptide.
Inventor(s):	DeFrees; Shawn (North Wales, PA), Zopf; David A. (Wayne, PA), Bayer; Robert J. (San Diego, CA), Bowe; Caryn (Doylestown, PA), Hakes; David James (Willow Grove, PA), Chen; Xi (Lansdale, PA)
Assignee:	Neose Technologies, Inc. (Horsham, PA)
Application Number:	10/492,261
Patent Claims:	1. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a covalent conjugate between a poly(alkylene oxide) and a glycosylated or non-glycosylated peptide, wherein said poly(alkylene oxide) is conjugated to said peptide via a glycosyl linking group wherein said glycosyl linking group is interposed between and covalently linked to both said peptide and said poly(alkylene oxide), wherein said covalent conjugate is formed by contacting said peptide with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said peptide, thereby forming said covalent conjugate, and wherein said modified sugar moiety comprises said poly(alkylene oxide). 2. The pharmaceutical composition of claim 1, wherein said polyalkylene oxide is a poly(ethylene glycol). 3. The pharmaceutical composition according to claim 2, wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse. 4. The pharmaceutical composition of claim 2, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol). 5. The pharmaceutical composition of claim 2, wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol). 6. The pharmaceutical composition of claim 1, wherein said glycosyltransferase is an oligosaccharyltransferase. 7. The pharmaceutical composition of claim 1, wherein said glycosyltransferase is selected from the group consisting of ST3Gal3, ST3Gal1, ST6GalNAcI and CST-II. 8. The pharmaceutical composition of claim 1 wherein, following said forming said covalent conjugate, said peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said peptide, thereby transferring a sialic acid moiety onto said peptide. 9. The pharmaceutical composition of claim 1, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, human growth hormone, BMP-2, BMP-52, FGF, and NT-3. 10. The pharmaceutical composition of claim 1, wherein said poly(alkylene oxide) and a glycosyl linking group precursor are linked as a covalently attached unit to said peptide via the action of an enzyme, said enzyme converting said precursor to said glycosyl linking group, thereby forming said covalent conjugate. 11. The pharmaceutical composition of claim 1, wherein said glycosyl linking unit is a member selected from the group consisting of a sialic acid residue, a Gal residue, a GlcNAc residue and a GalNAc residue. 12. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a covalent conjugate between a poly(alkylene oxide) and a peptide, wherein said peptide has the formula: ##STR00084## wherein AA is a terminal or internal amino acid residue of said peptide; X.sup.1-X.sup.2 is a saccharide covalently linked to said AA, wherein X.sup.1 is a first glycosyl residue; and X.sup.2 is a second glycosyl residue covalently linked to X.sup.1, wherein X.sup.1 and X.sup.2 are selected from monosaccharyl and oligosaccharyl residues; wherein a cell-free, in vitro method of forming said covalent conjugate comprises: (a) removing X.sup.2 or a saccharyl subunit thereof from said peptide, thereby forming a truncated glycan; and (b) contacting said truncated glycan with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said truncated glycan, wherein said modified sugar moiety comprises a poly(alkylene oxide), thereby forming said covalent conjugate of said peptide. 13. The pharmaceutical composition of claim 12, further comprising: (c) prior to step (b), removing a group added to said saccharide during post-translational modification. 14. The pharmaceutical composition of claim 13, wherein said group is a member selected from phosphate, sulfate, carboxylate and esters thereof. 15. The pharmaceutical composition of claim 12, wherein the peptide has the formula: ##STR00085## wherein Z is a member selected from O, S, NH, and a crosslinker. 16. The pharmaceutical composition of claim 12, wherein said poly(alkylene oxide) is a poly(ethylene glycol). 17. The pharmaceutical composition of claim 16, wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse. 18. The pharmaceutical composition of claim 16, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol). 19. The pharmaceutical composition of claim 16, wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol). 20. The pharmaceutical composition of claim 12, wherein said glycosyltransferase is an oligosaccharyltransferase. 21. The pharmaceutical composition of claim 12, wherein said glycosyltransferase is selected from the group consisting of ST3Gal3, ST3Gal1, ST6GalNAcI and CST-II. 22. The pharmaceutical composition of claim 12 wherein, following said forming said covalent conjugate, said peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said peptide, thereby transferring a sialic acid moiety onto said peptide. 23. The pharmaceutical composition of claim 12, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, human growth hormone, BMP-2, BMP-52, FGF. 24. The pharmaceutical composition of claim 12, wherein said peptide has the formula: ##STR00086## wherein X.sup.9 and X.sup.10 are independently selected from monosaccharyl and oligosaccharyl residues; and m, n and f are integers selected from 0 and 1. 25. The pharmaceutical composition of claim 12, wherein said peptide has the formula: ##STR00087## wherein X.sup.11 and X.sup.12 are independently selected glycosyl moieties; and r and x are integers independently selected from 0 and 1. 26. The pharmaceutical composition of claim 25, wherein X.sup.11 and X.sup.12 are (mannose).sub.q, wherein q is selected from the integers between 1 and 20, and when q is three or greater, (mannose).sub.q is selected from linear and branched structures. 27. The pharmaceutical composition of claim 25, wherein said glycosyltransferase comprises: (i) GNT-1; (ii) GalT1; and (iii) ST3Gal3. 28. The pharmaceutical composition of claim 12, wherein said peptide has the formula: ##STR00088## wherein X.sup.13, X.sup.14, and X.sup.15 are independently selected glycosyl residues; and g, h, i, j, k, and p are independently selected from the integers 0 and 1, with the proviso that at least one of g, h, i,j, k and p is 1. 29. The pharmaceutical composition of claim 28, wherein X.sup.14 and X.sup.15 are members independently selected from GlcNAc and Sia; and i and k are independently selected from the integers 0 and 1, with the proviso that at least one of i and k is 1, and if k is 1, g, h, and j are 0. 30. The pharmaceutical composition of claim 12, wherein said peptide has the formula: ##STR00089## wherein X.sup.16 is a member selected from: ##STR00090## wherein s, u and i are independently selected from the integers 0 and 1. 31. The pharmaceutical composition of claim 12, wherein said removing utilizes a glycosidase. 32. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a covalent conjugate between a poly(alkylene oxide) and a peptide, said peptide having the formula: ##STR00091## wherein AA is a terminal or internal amino acid residue of said peptide; X.sup.1 is a glycosyl residue covalently linked to said AA, selected from monosaccharyl and oligosaccharyl residues; and u is an integer selected from 0 and 1, wherein a cell-free, in vitro method of forming said covalent conjugate comprises: contacting said peptide with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said peptide, wherein said modified sugar moiety comprises a poly(alkylene oxide), thereby forming said covalent conjugate of said peptide. 33. The pharmaceutical composition of claim 32, wherein said poly(alkylene oxide) is a poly(ethylene glycol). 34. The pharmaceutical composition of claim 33, wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse. 35. The pharmaceutical composition of claim 33, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol). 36. The pharmaceutical composition of claim 33, wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol). 37. The pharmaceutical composition of claim 32, wherein said glycosyltransferase is an oligosaccharyltransferase. 38. The pharmaceutical composition of claim 32, wherein said glycosyltransferase is selected from the group consisting of ST3Gal3, ST3Gal1, ST6GalNAcI and CST-II. 39. The pharmaceutical composition of claim 32 wherein, following said forming said covalent conjugate, said peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said peptide, thereby transferring a sialic acid moiety onto said peptide. 40. The pharmaceutical composition of claim 32, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, human growth hormone, BMP-2, BMP-52, FGF. 41. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a covalent conjugate between a poly(alkylene oxide) and a peptide, said peptide having the formula: ##STR00092## wherein r, s, and t are integers independently selected from 0 and 1, wherein a cell-free, in vitro method of forming said covalent conjugate comprises: (a) contacting said peptide with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said peptide, wherein said modified sugar moiety comprises a poly(alkylene oxide), thereby forming said covalent conjugate of said peptide. 42. The pharmaceutical composition of claim 41, wherein said poly(alkylene glycol) is a poly(ethylene glycol). 43. The pharmaceutical composition of claim 42, wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse. 44. The pharmaceutical composition of claim 42, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol). 45. The pharmaceutical composition of claim 42, wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol). 46. The pharmaceutical composition of claim 41, wherein said glycosyltransferase is an oligosaccharyltransferase. 47. The pharmaceutical composition of claim 41, wherein said glycosyltransferase is selected from the group consisting of ST3Gal3, ST3Gal1, ST6GalNAcI and CST-II. 48. The pharmaceutical composition of claim 41, wherein said glycosyltransferase comprises: (i) GalT1; and (ii) ST3Gal3. 49. The pharmaceutical composition of claim 41 wherein, following said forming said covalent conjugate, said peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said peptide, thereby transferring a sialic acid moiety onto said peptide. 50. The pharmaceutical composition of claim 41, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, human growth hormone, BMP-2, BMP-52, FGF. 51. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a covalent conjugate between a poly(alkylene oxide) and a peptide, said peptide having the formula: ##STR00093## wherein AA is a terminal or internal amino acid residue of said peptide; X.sup.1-X.sup.2 is a saccharide covalently linked to said AA, wherein X.sup.1 is a first glycosyl residue; and X.sup.2 is a second glycosyl residue covalently linked to X.sup.1, wherein X.sup.1 and X.sup.2 are selected from monosaccharyl and oligosaccharyl residues; wherein a cell-free, in vitro method of forming said covalent conjugate comprises: (a) removing X.sup.1 and X.sup.2, exposing said AA; and (b) contacting said peptide with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said peptide, wherein said modified sugar moiety comprises a poly(alkylene oxide), thereby forming said covalent conjugate of said peptide. 52. The pharmaceutical composition of claim 51, wherein said water-soluble polymer is a poly(ethylene glycol). 53. The pharmaceutical composition of claim 52, wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse. 54. The pharmaceutical composition of claim 52, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol). 55. The pharmaceutical composition of claim 52, wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol). 56. The pharmaceutical composition of claim 51, wherein said glycosyltransferase is an oligosaccharyltransferase. 57. The pharmaceutical composition of claim 51, wherein said glycosyltransferase is selected from the group consisting of ST3Gal3, ST3Gal1, ST6GalNAcI and CST-II. 58. The pharmaceutical composition of claim 51 wherein, following said forming said covalent conjugate, said peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said peptide, thereby transferring a sialic acid moiety onto said peptide. 59. The pharmaceutical composition of claim 51, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, human growth hormone, BMP-2, BMP-52, FGF. 60. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a covalent conjugate between a poly(alkylene oxide) and a peptide, said peptide having the formula: ##STR00094## wherein X.sup.3, X.sup.4, X.sup.5, X.sup.6, X.sup.7, and X.sup.17 are independently selected from monosaccharyl and oligosaccharyl residues; and a, b, c, d, e and x are independently selected from the integers 0, 1 and 2, with the proviso that at least one member selected from a, b, c, d, and e and x is 1 or 2; wherein a cell-free, in vitro method of forming said covalent conjugate comprises: (a) removing at least one of X.sup.3, X.sup.4, X.sup.5, X.sup.6, X.sup.7, or X.sup.17, or a saccharyl subunit thereof from said peptide, thereby forming a truncated glycan; and (b) contacting said truncated glycan with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said truncated glycan, wherein said modified sugar moiety comprises a poly(alkylene oxide), thereby forming said covalent conjugate of said peptide. 61. The pharmaceutical composition of claim 60 wherein said removing of step (a) produces a truncated glycan in which a, b, c, e and x are each 0. 62. The pharmaceutical composition of claim 60 wherein X.sup.3, X.sup.5, and X.sup.7, are selected from the group consisting of (mannose).sub.z and (mannose).sub.z--(X.sup.8).sub.y wherein X.sup.8 is a glycosyl moiety selected from mono- and oligo-saccharides; y is an integer selected from 0 and 1; and z is an integer between 1 and 20, wherein when z is 3 or greater, (mannose).sub.z is selected from linear and branched structures. 63. The pharmaceutical composition of claim 60 wherein X.sup.4 is selected from the group consisting of GlcNAc and xylose. 64. The pharmaceutical composition of claim 60 wherein X.sup.3, X.sup.5, and X.sup.7 are (mannose).sub.u, wherein u is selected from the integers between 1 and 20, and when u is 3 or greater, (mannose).sub.u is selected from linear and branched structures. 65. The pharmaceutical composition of claim 60, wherein said poly(alkylene oxide) is a poly(ethylene glycol). 66. The pharmaceutical composition of claim 65, wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse. 67. The pharmaceutical composition of claim 65, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol). 68. The pharmaceutical composition of claim 65, wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol). 69. The pharmaceutical composition of claim 60, wherein said glycosyltransferase is an oligosaccharyltransferase. 70. The pharmaceutical composition of claim 60, wherein said glycosyltransferase is selected from the group consisting of ST3Gal3, ST3Gal1, ST6GalNAcI and CST-II. 71. The pharmaceutical composition of claim 60 wherein, following said forming said covalent conjugate, said peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said peptide, thereby transferring a sialic acid moiety onto said peptide. 72. The pharmaceutical composition of claim 60, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, human growth hormone, BMP-2, BMP-52, FGF. 73. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a covalent conjugate between a poly(alkylene oxide) and a peptide, wherein said poly(alkylene oxide) is conjugated to said peptide via an intact glycosyl linking group interposed between and covalently linked to both said peptide and said poly(alkylene oxide), wherein a cell-free, in vitro method of forming a covalent conjugate comprises: contacting said peptide with a mixture comprising a nucleotide sugar covalently linked to said poly(alkylene oxide), and a glycosyltransferase for which said nucleotide sugar is a substrate under conditions suitable for said glycosyltransferase to transfer a modified sugar moiety of said nucleotide sugar to said peptide, wherein said modified sugar moiety comprises a poly(alkylene oxide), thereby forming said covalent conjugate of said peptide. 74. The pharmaceutical composition of claim 73, wherein said glycosyl linking group is covalently attached to a glycosyl residue covalently attached to said peptide. 75. The pharmaceutical composition of claim 73, wherein said glycosyl linking group is covalently attached to an amino acid residue of said peptide. 76. The pharmaceutical composition of claim 73, wherein said glycosyltransferase is selected from the group consisting of sialyltransferase, galactosyltransferase, glucosyltransferase, GalNAc transferase, GlcNAc transferase, fucosyltransferase, and mannosyltransferase. 77. The pharmaceutical composition of claim 73, wherein said glycosyltransferase is recombinantly produced. 78. The pharmaceutical composition of claim 77, wherein said glycosyltransferase is a recombinant prokaryotic enzyme. 79. The pharmaceutical composition of claim 77, wherein said glycosyltransferase is a recombinant eukaryotic enzyme. 80. The pharmaceutical composition of claim 73, wherein said nucleotide sugar is selected from the group consisting of UDP-glycoside, CMP-glycoside, and GDP-glycoside. 81. The pharmaceutical composition of claim 80, wherein said nucleotide sugar is selected from the group consisting of UDP-galactose, UDP-galactosamine, UDP-glucose, UDP-glucosamine, UDP-N-acetylgalactosamine, UDP-N-acetylglucosamine, GDP-mannose, GDP-fucose, CMP-sialic acid, and CMP-NeuAc. 82. The pharmaceutical composition of claim 73, wherein said peptide is a therapeutic agent. 83. The pharmaceutical composition of claim 73, wherein said glycosylated peptide is partially deglycosylated prior to said contacting. 84. The pharmaceutical composition of claim 73, wherein said intact glycosyl linking group is a sialic acid residue. 85. The pharmaceutical composition of claim 73, wherein said method is performed in a cell-free environment. 86. The pharmaceutical composition of claim 73, wherein said covalent conjugate is isolated. 87. The pharmaceutical composition of claim 86, wherein said covalent conjugate is isolated by membrane filtration. 88. The pharmaceutical composition of claim 73, wherein said poly(alkylene glycol) is a poly(ethylene glycol). 89. The pharmaceutical composition of claim 88, wherein said poly(ethylene glycol) has a degree of polymerization from about 1 to about 40,000. 90. The pharmaceutical composition of claim 88, wherein said poly(ethylene glycol) has a degree of polymerization from about 1 to about 80,000, and further wherein said poly(ethylene glycol) is a branched structure. 91. The pharmaceutical composition of claim 88, wherein said poly(ethylene glycol) has a mass from about 10 kDa to about 40 kDa. 92. The pharmaceutical composition of claim 88, wherein said poly(ethylene glycol) has a degree of polymerization from about 1 to about 30,000, and further wherein said poly(ethylene glycol) is a linear structure. 93. The pharmaceutical composition of claim 89, wherein said poly(ethylene glycol) has a degree of polymerization from about 1 to about 5,000. 94. The pharmaceutical composition of claim 93, wherein said poly(ethylene glycol) has a degree of polymerization from about 1 to about 1,000. 95. The pharmaceutical composition of claim 88, wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse. 96. The pharmaceutical composition of claim 88, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol). 97. The pharmaceutical composition of claim 88, wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol). 98. The pharmaceutical composition of claim 73, wherein said glycosyltransferase is an oligosaccharyltransferase. 99. The pharmaceutical composition of claim 73, wherein said glycosyltransferase is selected from the group consisting of ST3Gal3, ST3Gal1, ST6GalNAcI and CST-II. 100. The pharmaceutical composition of claim 73 wherein, following said forming said covalent conjugate, said peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said peptide, thereby transferring a sialic acid moiety onto said peptide. 101. The pharmaceutical composition of claim 73, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, human growth hormone, BMP-2, BMP-52, FGF. 102. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a covalent conjugate between a poly(alkylene oxide) and a peptide, said peptide having the formula: ##STR00095## wherein AA is a terminal or internal amino acid residue of said peptide, wherein a cell-free, in vitro method of forming said covalent conjugate comprises: contacting said peptide with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said amino acid residue, wherein said modified sugar moiety comprises a poly(alkylene oxide), thereby forming said covalent conjugate of said peptide. 103. The pharmaceutical composition of claim 102, wherein said poly(alkylene glycol) is a poly(ethylene glycol). 104. The pharmaceutical composition of claim 103, wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse. 105. The pharmaceutical composition of claim 103, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol). 106. The pharmaceutical composition of claim 103, wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol). 107. The pharmaceutical composition of claim 102, wherein said glycosyltransferase is an oligosaccharyltransferase. 108. The pharmaceutical composition of claim 102, wherein said glycosyltransferase is selected from the group consisting of GalNAcT2, ST3Gal1, ST3Gal3, ST6GalNAcI, CST-I, CST-II and combinations thereof. 109. The pharmaceutical composition of claim 108, wherein said at least one glycosyltransferase is GalNAcT2, followed by a member selected from ST3Gal1, ST3Gal3, ST6GalNAcI, CST-I, CST-II and combinations thereof. 110. The pharmaceutical composition of claim 102 wherein, following said forming said covalent conjugate, said peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said peptide, thereby transferring a sialic acid moiety onto said peptide. 111. The pharmaceutical composition of claim 102, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, human growth hormone, BMP-2, BMP-52, FGF. 112. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a covalent conjugate between a poly(alkylene oxide) and a peptide, wherein said poly(alkylene oxide) is covalently attached to said peptide through an intact glycosyl linking group, said peptide having the formula: ##STR00096## wherein h is 1; a, b, c, d, e, f and g are 1; j, k, l and m are 1; i is 0; n, v, w, x and y are 0; and R is said poly(alkylene oxide), wherein a cell-free, in vitro method of forming said covalent conjugate comprises: (a) contacting said peptide with at least one glycosyltransferase and at least one modified sugar donor under conditions suitable for said at least one glycosyltransferase to transfer a modified sugar moiety of said at least one modified sugar donor to said peptide, wherein said modified sugar moiety comprises a poly(alkylene oxide) such that following said transfer at least one of v, w, x or y is 1, thereby forming said intact glycosyl linking group. 113. The pharmaceutical composition of claim 112, wherein said poly(alkylene glycol) is a poly(ethylene glycol). 114. The pharmaceutical composition of claim 113, wherein said poly(ethylene glycol) has a molecular weight that is essentially homodisperse. 115. The pharmaceutical composition of claim 113, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol). 116. The pharmaceutical composition of claim 113, wherein said poly(ethylene glycol) is monomethoxy-poly(ethylene glycol). 117. The pharmaceutical composition of claim 112, wherein said glycosyltransferase is an oligosaccharyltransferase. 118. The pharmaceutical composition of claim 112, wherein said glycosyltransferase is selected from the group consisting of ST3Gal3 and CST-II. 119. The pharmaceutical composition of claim 112 wherein, following said forming said covalent conjugate, said peptide is contacted with a sialic acid donor and a sialyltransferase under conditions suitable for said sialyltransferase to transfer a sialic acid residue onto said peptide, thereby transferring a sialic acid moiety onto said peptide. 120. The pharmaceutical composition of claim 112, wherein said peptide is selected from the group consisting of granulocyte colony stimulating factor, interferon-alpha, interferon-beta, follicle stimulating hormone, erythropoietin, granulocyte macrophage colony stimulating factor, interferon-gamma, alpha-1-protease inhibitor, beta-glucosidase, tissue plasminogen activator protein, interleukin-2, chimeric tumor necrosis factor receptor, urokinase, chimeric anti-glycoprotein IIb/IIIa antibody, chimeric anti-HER2 antibody, chimeric anti-respiratory syncytial virus antibody, chimeric anti-CD20 antibody, DNase, chimeric anti-tumor necrosis factor antibody, human insulin, hepatitis B sAg, human growth hormone, BMP-2, BMP-52, FGF.

Details for Patent 7,416,858

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	January 16, 1978	7,416,858	2040-03-31
Novo Nordisk Inc.	REBINYN	coagulation factor ix (recombinant), glycopegylated	For Injection	125611	May 31, 2017	7,416,858	2040-03-31
Novo Nordisk Inc.	REBINYN	coagulation factor ix (recombinant), glycopegylated	For Injection	125611	August 11, 2022	7,416,858	2040-03-31